a study on Multiple Myeloma
This study will evaluate the safety of LBH589 given in combination with lenalidomide and dexamethasone in adult patients with multiple myeloma
A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Oral Lenalidomide & Dexamethasone in Adult Patients With Multiple Myeloma
Multiple Myeloma Myeloma Lenalidomide Revlimid Dexamethasone LBH589 Combination Panobinostat Dexamethasone acetate Dexamethasone 21-phosphate BB 1101
Open to people ages 18 years and up
Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff.
Other protocol defined inclusion/exclusion criteria may apply
© 2017 The Regents of the University of California